Prior corticosteroid treatment alters cPBMC composition and IFNγ response to immunotherapy in canine cancer
BackgroundImmunotherapy using immune checkpoint inhibitors (ICIs) represents a promising therapeutic approach for canine cancer patients. Similar to human cancer patients, the concurrent use of corticosteroids may attenuate the efficacy of immune checkpoint inhibitors in dogs. In this study, we eval...
Saved in:
| Main Authors: | Anna Barbara Emilia Zimmermann, Betül Taskoparan, Daniel Fuchs, Stanislav Pantelyushin, Mathischan Maheswaran, Manuela Schnyder, Sonja Hartnack, Carla Rohrer Bley, Johannes vom Berg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1544949/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
by: Samaneh Moradi, et al.
Published: (2025-03-01) -
Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01) -
IFN-Alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying cc genotype. possible role of IFN-lambda.
by: Eleonora Lalle, et al.
Published: (2014-01-01) -
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)
by: Giulia Pasello, et al.
Published: (2025-06-01) -
Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)